Zhao, L;
Varghese, Z;
Moorhead, JF;
Chen, Y;
Ruan, XZ;
(2018)
CD36 and lipid metabolism in the evolution of atherosclerosis.
British Medical Bulletin
, 126
(1)
pp. 101-112.
10.1093/bmb/ldy006.
Preview |
Text
s1-ln2119481295844769-1939656818Hwf711356491IdV-25173490321194812PDF_HI0001 (1).pdf - Accepted Version Download (1MB) | Preview |
Abstract
Background: CD36 is a multi-functional class B scavenger receptor, which acts as an important modulator of lipid homeostasis and immune responses. Sources of data: This review uses academic articles. Areas of agreement: CD36 is closely related to the development and progression of atherosclerosis. Areas of controversy: Both persistent up-regulation of CD36 and deficiency of CD36 increase the risk for atherosclerosis. Abnormally up-regulated CD36 promotes inflammation, foam cell formation, endothelial apoptosis, macrophage trapping and thrombosis. However, CD36 deficiency also causes dyslipidemia, subclinical inflammation and metabolic disorders, which are established risk factors for atherosclerosis. Growing points: There may be an 'optimal protective window' of CD36 expression. Areas timely for developing research: In addition to traditionally modulating protein functions using gene overexpression or deficiency, the modulation of CD36 function at post-translational levels has recently been suggested to be a potential therapeutic strategy.
Archive Staff Only
 |
View Item |
